Senti de la companya Office of the Science are

RECEIVED BY:

NINETEENTH CONGRESS OF THEREPUBLIC OF THE PHILIPPINESFirst Regular Session

1.4

. .

22 JUL 13 P2:58

SENATE

s. No. 522

Introduced by SENATOR CYNTHIA A. VILLAR

AN ACT

STRENGTHENING THE REGULATORY SYSTEM IN THE COUNTRY TO COMBAT COUNTERFEIT PHARMACEUTICAL PRODUCTS, DECLARING THE MANUFACTURE, IMPORTATION, DISTRIBUTION, SALE OR OFFER FOR SALE, OR POSSESSION OF COUNTERFEIT PHARMACEUTICAL PRODUCTS AS AN OFFENSE INVOLVING ECONOMIC SABOTAGE, PROVIDING FOR THE PROHIBITIONS AND PENALTIES FOR VIOLATIONS AND REVISING FOR THE PURPOSE REPUBLIC ACT NO. 8203 OR THE "SPECIAL LAW ON COUNTERFEIT DRUGS"

EXPLANATORY NOTE

Since the enactment in 1996 of Republic Act (RA) No. 8203, otherwise known as the "Special Law on Counterfeit Drugs", the following subsequent laws were enacted by Congress affecting certain provisions of Ra No. 8203. namely: a.) RA No. 9502 (Cheaper Medicines Law); b.) RA No. 9711 (FDA Act); c.) RA No. 10918 (Philippine Pharmacy Law) on the definition of drugs; d.) RA No. 10175 (Cybercrime Prevention Act of 2012) concerning certain prohibited acts in Section 4 of RA No. 8203 (online selling, online service, online pharmacy); and e.) RA No. 10918 (Philippine Pharmacy Law) on the definition of counterfeit drugs, as well as in declaring registered pharmacists liable under RA No. 10918, apart from liability under RA No. 8203.

Undeniably, in twenty six (26) years since Republic Act No. 8203 was enacted, there have been many changes in the industry and in anti-counterfeiting technologies, but the continuing real threat that counterfeit pharmaceutical products

present to our health, to the security of our family especially our children, and our collective safety cannot be overemphasized. It cannot be denied that we are faced by a rapidly growing flood of illicit and dangerous pharmaceutical products.

This problem is even more compounded as we have witnessed in the last decade a growth in internet sales of pharmaceutical products and this has been associated with the increasing cases of counterfeit pharmaceutical products entering and moving through countries worldwide, including the Philippines. Given the vast, almost limitless possibilities of the internet, and borderless movement of goods, it undeniably becomes even more challenging for the Food and Drug Administration (FDA) to combat the distribution of counterfeit pharmaceutical products.

Thus, there is a need to safeguard the interest of the general public and the government, particularly the Food and Drug Administration under the Department of Health, against the syndicated or highly organized operations of unscrupulous persons engaged in the illegal manufacture, importation, distribution, sale or possession of counterfeit pharmaceutical products.

Undeniably, these illegal operations threaten to undermine the people's confidence in the health regulatory system and have already resulted in the loss of considerable government revenues.

During the previous administration, the Philippine National Police conducted an operation to arrest persons involved in the manufacture, importation, trade, administration, delivery and distribution of counterfeit drugs and charge them with economic sabotage. The acts of those involved in counterfeit pharmaceutical products undermine not only the economy (because of its effect on the law of supply and demand and the prices), but also threaten the security of the nation because it pose danger to the health of the people.¹

This is the reason behind this proposed bill. The bill incorporates as economic sabotage the illegal manufacture, importation, distribution, sale or offer for sale, or possession of counterfeit pharmaceutical products to a certain extent to emphasize

¹ https://newsinfo.inquirer.net/978785/duterte-fake-medicine-pnp-arrest-fda-counterfeit-drugs


the seriousness of the prohibited acts and their highly deleterious effect on people's lives.

1.3

In view of the foregoing, immediate passage of this bill is earnestly sought.

CYNTHIA A. VILLAR

NINETEENTH CONGRESS OF THE) REPUBLIC OF THE PHILIPPINES) *First Regular Session*)



22 JUL 13 P2:58

RECEIVED E

SENATE

S. No. 522

Introduced by SENATOR CYNTHIA A. VILLAR

AN ACT

STRENGTHENING THE REGULATORY SYSTEM IN THE COUNTRY TO COMBAT COUNTERFEIT PHARMACEUTICAL PRODUCTS, DECLARING THE MANUFACTURE, IMPORTATION, DISTRIBUTION, SALE OR OFFER FOR SALE, OR POSSESSION OF COUNTERFEIT PHARMACEUTICAL PRODUCTS AS AN OFFENSE INVOLVING ECONOMIC SABOTAGE, PROVIDING FOR THE PROHIBITIONS AND PENALTIES FOR VIOLATIONS AND REVISING FOR THE PURPOSE REPUBLIC ACT NO. 8203 OR THE "SPECIAL LAW ON COUNTERFEIT DRUGS"

Be it enacted by the Senate and House of Representatives of the Philippines in Congress assembled:

CHAPTER I

GENERAL PROVISIONS

Section 1. Short Title. – This Act shall be known as the "Counterfeit
 Pharmaceutical Products Prevention Act".

Sec. 2. *Declaration of Policy.* – It is the policy of the State, under Article II,
Section 15 of the 1987 Constitution, to protect and promote the right to health of
the 38 people and instill health consciousness among them.

6 The 1987 Constitution also provides, under Article XIII, Section 12, that: The 7 State shall establish and maintain an effective food and drug regulatory system and 8 undertake appropriate health manpower development and research, responsive to 9 the country's health needs and problems. Pursuant to the above policies, the State must adopt, support, establish, institutionalize, improve and maintain structures, processes, mechanisms and initiatives that are aimed, directed and designed to strengthen its capability to prevent activities that may result, or detect, investigate, suppress, and more effectively respond to actions that result in counterfeit pharmaceutical products.

6 It shall likewise provide for the strengthening of prohibitions against 7 counterfeit pharmaceutical products; declare the manufacture, importation, 8 distribution, sale or offer for sale, or possession of counterfeit pharmaceutical 9 products as offenses involving economic sabotage; and provide stricter penalties for 10 violations of the Act

11

Sec. 3. *Definition of Terms.* – As used in this Act:

- a) "Brokering" shall refer to any act of facilitating the disposal or sale of
 counterfeit pharmaceutical products, including acts of agency.
- b) "Biopharmaceuticals" shall refer to pharmaceutical products that are used for therapeutic or for in vivo diagnostic purposes, such as vaccines, sera, and drugs derived from life forms using biotechnology. These include proteins, nucleic acids, or living microorganisms where the virulence is reduced and are used for therapeutic or for in vivo diagnostic purposes.
- 20 c) "CDRR" shall refer to the Center for Drug Regulation and Research of21 the FDA.
- d) "Counterfeit pharmaceutical products" shall refer to pharmaceutical
 products which fall under any of the following conditions, which results
 in the reduction of the pharmaceutical products' safety, efficacy,
 quality, strength or purity:
- i. do not contain the amounts as claimed;
- ii. with wrong ingredients;

1

.

- iii. without active ingredients; or
- iv. with less than eighty percent (80%) of the active ingredient it
 purports to possess as distinguished from an adulterated drug
 including reduction or loss of efficacy due to expiration.

5 It shall also refer to products that are deliberately and fraudulently 6 misrepresented with respect to their identify, composition and/or source. For this 7 purpose, the terms:

- 8 i. "Identity" shall refer to the name, labelling or packaging or to
 9 documents that support the authenticity of an authorized
 10 pharmaceutical product.
- ii. "Composition" shall refer to any ingredient or component of the
 pharmaceutical product in accordance with applicable
 specifications authorized/recognized by the FDA.
- iii. "Source" shall refer to the identification, including name and
 address, of the marketing authorization holder, manufacturer,
 importer, exporter, distributor or retailer, as applicable.

Any consideration related to intellectual property rights does not fall withinthis definition.

- e) "Director General" shall refer to the Director General of the FDA.
- f) "Drugs" shall refer to pharmaceutical products that pertain to any
 chemical compound or biological substance, other than food, intended
 for use in the treatment, cure, mitigation, prevention or diagnosis of
 disease in humans or animals, including but not limited to:
- i. any article recognized in the Philippine Pharmacopoeia,
 Philippine National Drug Formulary, or in any foreign official
 pharmacopoeias and formularies which are adopted by the FDA
 or any documentary supplement to any of them;

1 ii. any article, other than food, intended to affect the structure or 2 any function of the human body or animals; 3 iii. any article intended for use as a component of any chemical 4 compound or biological substance or articles specified above, 5 not including devices or their components, parts, or accessories; 6 or 7 iv. herbal and/or traditional drug which are articles of plant or 8 animal origin used in folk medicine, which are: 9 recognized in the Philippine National Drug Formulary; or i. 10 ii. intended for use in the treatment, cure, mitigation, 11 prevention or diagnosis of disease symptoms, injury or 12 body defects in humans; or 13 iii. other than food, intended to affect the structure or any 14 function of the human body; and 15 iv. in finished or ready-to-use dosage form; or 16 intended for use as a component of any of the articles ٧. 17 specified in clauses (i), (ii), (iii), and (iv); 18 g) Department shall refer to the Department of Health. 19 h) "Economic Sabotage" shall refer to any of the acts which are declared 20 unlawful and prohibited under this Act when committed and the 21 amount of the counterfeit pharmaceutical product(s) involve (whether 22 as a single product or totality of different pharmaceutical products) is 23 One Million Pesos (PhP1,000,000.00) or more, as valued by the Food 24 and Drug Administration, any provision of law to the contrary 25 notwithstanding.

. .

i) "Establishment" shall refer to a sole proprietorship, a partnership, a
 corporation, an institution, an association, or an organization engaged
 in the manufacture, importation, exportation, sale, offer for sale,
 distribution, donation, transfer, use, testing, promotion, advertising, or
 sponsorship of pharmaceutical product, including the facilities and
 installations needed for its activities.

- 7 j) "FDA" shall refer to the Food and Drug Administration.
- 8 k) "FDRO" shall refer to the Food and Drug Regulation Officer of theFDA.
- 9 I) "LSD" shall refer to the laboratories under the FDA including those
 10 private laboratories accredited by the agency to conduct particular
 11 scope of analysis.
- 12 m) "SSC" shall refer to the Legal Services Support Center of the FDA.
- n) "Medicines" shall refer to drugs in their appropriate dosage forms, with
 assured quality, safety and efficacy for humans or animals, or both.
- o) "Online Service" shall refer to the sale, offering for sale, donation,
 distribution, trafficking, brokering of pharmaceutical product, or the
 sale of any punch, dye, plate or any other equipment or instrument
 designed to print, imprint or reproduce the trademark, trade name or
 other identifying mark for use to any pharmaceutical product, through
 and with the use of information and communication technology system.
 The term shall also cover Online Selling or Online Pharmacy Services.
- p) "Owner" shall refer to a person or group of persons who is the
 registered owner of a license to operate a business or business
 undertaking in the Philippines or the branch manager or operator,
 license, franchise, or any person acting on behalf of the corporate
 entity.

1q)"Pharmaceutical Products" shall refer to drugs, medicines, biologicals,2pharmaceutical and biopharmaceutical products/specialties, veterinary3products, veterinary biologics and veterinary medicinal products.

r) "Residence" shall refer to a private dwelling or abode where a person
lives, either as owner or lessee, or usufructuary including, for purposes
of this Act, its yard_garage, storage rooms or premises; provided that
where the yard, garage, storage rooms or premises are used to
manufacture, process, pack, or hold pharmaceutical products for
introduction into domestic commerce, the same shall not fall as
residence but be considered as establishment.

Sec. 4. *Prohibited Acts.* – The following acts are declared unlawful and
therefore, prohibited:

13 14

15

 The manufacture, importation, distribution, sale, offering for sale, donation, trafficking, brokering, exportation, or possession of counterfeit pharmaceutical products as defined in Section 3 hereof.

Any provision of law to the contrary notwithstanding, when any of the acts in the preceding paragraph is committed and the amount of the counterfeit pharmaceutical product(s) involve (whether as a single product or totality of different pharmaceutical products) is One Million Pesos (PhP1,000,000.00) or more, as valued by the Food and Drug Administration, they shall be deemed as an offense involving economic sabotage.

The presence or availability of such counterfeit pharmaceutical product within the premises of any entity engaged in the manufacture, importation, distribution, sale, offering for sale, donation, trafficking, brokering, exportation, of pharmaceutical products or in a private residence, or in public or private vehicle, shall constitute a prima facie evidence of violation of this Act.

The above presumption shall not apply to the legitimate owners of trademarks, trade names or other identifying marks, or the legitimate or authorized representatives or agents of such owners, who have in their possession counterfeit

1 pharmaceutical products which bear the trademarks, trade names or marks if they 2 can show the sales invoices or official receipts evidencing their purchase from a 3 drugstore, manufacturer or distributor suspected by them of dealing in counterfeit 4 drugs involving the trademarks, trade names and other similar identifying marks 5 registered in their names: Provided, that such counterfeit pharmaceutical products 6 shall be reported and immediately turned over to the FDA within a period of ten (10) 7 days from the date of purchase of such counterfeit pharmaceutical product as 8 indicated in the sales invoice, official receipt, or other similar documents 9 abovementioned to the time the counterfeit pharmaceutical products are reported 10 and turned over to the FDA.

- b) Possession of any such counterfeit pharmaceutical product. However,
 any person found in possession of counterfeit pharmaceutical product,
 in violation of this subsection, shall be exempted from liability under
 the provisions of this Act after:
- 15a.Presentation of sales invoices, official receipt or other legally16acceptable documents evidencing his purchase thereof from a17drugstore, distributor, manufacturer, hospital pharmacy or18dispensary; or any other person or place duly licensed to sell19and/or dispense pharmaceutical product, and indicating therein20the batch and lot numbers, as well as the expiry dates of such21pharmaceutical product; or
- b. Presentation of certificates and other documents evidencing the
 importation or exportation of the counterfeit pharmaceutical
 product found in his possession as required by existing laws,
 including those documents required in the preceding paragraph
 covering the commercial transactions involving counterfeit
 drugs;

In both cases, the subject counterfeit pharmaceutical product must not on its face appear to be as such, or do not bear any marking or any patently unusual characteristic sufficient to arouse the suspicion of a reasonable and prudent person that such pharmaceutical product is counterfeit. Furthermore, the amount or volume

of counterfeit pharmaceutical product held is such that it does not negate or is
inconsistent with the averment that the same are for personal use, notwithstanding
the presentation by the possessor of medical records and other similar documents
accompanying and justifying the use of such pharmaceutical product.

5 When the amount of the counterfeit pharmaceutical product(s) in possession 6 of any person (whether as a single product or totality of different pharmaceutical 7 products) is One Million Pesos (P1,000,000.00) or more, as valued by the Food and 8 Drug Administration, the act of possession shall be deemed as an offense involving 9 economic sabotage.

- 10 C) Photocopying, duplicating, altering, printing, transferring, obliterating 11 or removing the approved label or any part thereof, lawfully belonging 12 to another person, for the purpose of using such label or a part thereof 13 on any counterfeit pharmaceutical product: Provided, that if the person 14 who committed any of the acts enumerated in this paragraph and the 15 person who used the labels produced thereby are not one and the 16 same person and the former had knowledge of the purpose for which 17 the labels are intended, the former shall also be liable under the act 18 notwithstanding the failure of the latter to achieve the intended 19 purpose; and
- d) Making, selling, or concealing any punch, dye, plate or any other
 equipment or instrument designed to print, imprint or reproduce the
 trademark, trade name or other identifying mark of another registered
 producer or any likeness thereof, upon any pharmaceutical product or
 device or its container or label without authority from the legitimate
 owners of the trademark or trade name.
- Sec. 5. *Parties Liable.* The following persons shall be liable for violation(s) of
 the act:

a) the manufacturer, importer exporter, distributor, seller, distributor,
 trafficker, broker or donor of the counterfeit pharmaceutical product
 and their agents, as the case may be;

. *

- 4 b) the possessor of counterfeit pharmaceutical product as provided in
 5 Section 4(b) of this Act;
- 6 c) the manager, operator or lessee of the laboratory or laboratory
 7 facilities used in the manufacture of counterfeit pharmaceutical
 8 product;
- 9 d) the owner, proprietor, administrator or manager of the drugstore, 10 hospital pharmacy or dispensary, laboratory or other outlets or 11 premises where the counterfeit pharmaceutical product is found who 12 induces, causes or allows the commission of any act herein prohibited;
- e) the licensed and registered pharmacist of the establishment, or the
 licensed and registered pharmacist of the outlet where the counterfeit
 pharmaceutical product is sold or found, who sells or dispenses such
 drug to a third party; and
- f) should the offense be committed by a juridical person the penalty shall
 be imposed upon the officer or officers of the corporation, partnership,
 association or entity responsible for the violation; and if such officer is
 an alien, he shall, in addition to the penalties herein prescribed be
 deported without further proceedings.
- Sec. 6. *Liability under Other Laws.* A prosecution under this Act shall be
 without prejudice to any liability for violation of any provisions of other laws.
- Sec. 7. *Administrative Proceedings.* The FDA is hereby further authorized to
 undertake the following administrative actions.
- 26 I. Procedure When Counterfeit pharmaceutical product Is Monitored In the27 Market Pursuant To A Routine Inspection of the FDRO.

1 If the FDRO, in the course of his/her routine/regular inspection of a factory, 2 warehouse, establishment in which drugs are manufactured, processed, packed, or 3 held, for introduction into domestic commerce, or vehicle, and all pertinent 4 equipment, finished or unfinished materials, containers, and labeling therein, upon 5 the authority conferred by Section of Republic Act No. 3720 as amended, shall 6 suspect certain stocks as counterfeit pharmaceutical product, the FDRO shall 7 conduct an inventory, segregate and seal the suspected stocks, and collect samples 8 for examination as to the pharmaceutical product's genuineness and authenticity;

- 9 II. Procedure When Information is Received About the Presence of Counterfeit10 pharmaceutical product in the Possession of Any person or Establishment.
- 11 a) Any information, either referred by the government office or officer or 12 from anonymous sources or person requesting confidentiality of their 13 identities, on the existence of suspected counterfeit pharmaceutical 14 product in the possession of any manufacturer, seller or distributor, 15 shall undergo the verification process by the FDRO, or any officer 16 deputized or authorized by the Director General. Verification process 17 shall follow the existing system and procedure in the conduct of case build-up, investigation or other appropriate interventions adopted by 18 19 the FDA.
- 20 b) If the counterfeit pharmaceutical product is located in an21 establishment:
- i. Seize the counterfeit pharmaceutical product and take them intocustody; and
- 24 ii. Proceed in filing a criminal complaint and/or administrative25 complaint.
- 26 c) If the counterfeit pharmaceutical product is located in a private
 27 residence:
- 28 i. Secure a valid search warrant from a competent court;

- 1ii.After having obtained the search warrant, inventory and seize2such counterfeit pharmaceutical product and take them into3custody; and
- 4
- 5
- iii. Proceed in filing a criminal complaint and/or administrative complaint.
- 6 III. Findings of Counterfeit Drug/Medicine by Owners of Trademarks, Trade
 7 Names or Other Identifying Marks. Owners of trademarks, trade names or
 8 other identifying marks, or their authorized agents who have found their
 9 pharmaceutical product being counterfeited shall file an administrative case
 10 before the FDA following the procedure in the preceding section.

Sec. 8. *Hearing of Administrative Complaints and Institution of Criminal Action.* – The FDA shall hear and decide administrative complaints filed before the agency following the rules of procedure provided under Republic Act No. 3720, as amended, and its Implementing Rules and Regulations.

Upon preliminary findings of the conduct of prohibited acts, the Director General shall issue the proper notices or orders to the person or persons concerned and such person or persons shall he given an opportunity to he heard before the FDA.

Preventive Closure Order. A summons with preventive closure order shall be issued against the warehouse, building, factory, store, shop or any other structure where the said counterfeit pharmaceutical product are contained or stored within fifteen (15) days upon the filing of administrative complaint. This is for the purpose of preventing the disposition or tampering of evidence, the continuance of acts being complained of, and/or the flight of the Respondent.

After the lapse of the 30-day period, the preventive closure order is deemed
lifted without prejudice to the resolution of the case.

When any violation of any provisions of this Act comes to the knowledge of the Director General, of such character that a criminal prosecution ought to be

instituted against the offender, he shall certify the facts together with the laboratory
 report, the findings of the FDA, or other documentary evidence on which the charge
 is based.

Both criminal and administrative actions may be instituted separately and
independent of one another.

The Director General is hereby authorized to call on the assistance of any
Department, Office or Agency for the effective implementation of the provisions of
this Act.

9 Sec. 9. Penalties.

10 A. ADMINISTRATIVE SANCTIONS AND OTHER REMEDIES

11 Upon finding that the pharmaceutical product examined is counterfeit and the 12 determination of the parties liable thereof, the FDA shall impose any or all of the 13 following administrative penalties and/or pursue other remedies:

- *Minimum Penalty*. An administrative fine of not less than One hundred
 thousand pesos (₱100,000.00) but not more than Three hundred
 thousand pesos (₱300,000.00) shall be the minimum administrative
 penalty.
- *Medium Penalty*. An administrative fine of at least Three hundred
 thousand pesos (₱300,000.00) but less than Five hundred thousand
 pesos (₱ 500,000.00) and suspension or revocation of its license to do
 business shall be the medium administrative penalty.
- *Maximum Penalty*. An administrative fine of Five hundred thousand
 pesos (₱500,000.00) and permanent closure of the establishment
 concerned as well as the revocation of its license to do business shall
 be the maximum administrative penalty.

26 Provided, that if any or all of the instances below occur, the maximum 27 imposable fine of least five hundred thousand pesos (P 500,000.00), revocation of

its license to do business and permanent closure of establishment, and permanent
disqualification of the person concerned whether natural or juridical, from owning or
operating a drug establishment or outlet, as the case maybe, shall be imposed:

- a) If the Respondent or any of his officer or agent shall conceal,
 substitute, dispose or destroy any pharmaceutical product that may
 have been segregated and sealed by the; or
- b) If the Respondent or any of his officer or agent shall break, alter or
 tamper any mark or seal used by the FDA to identify those segregated
 drugs; or
- 10 c) As a result of the use of the pharmaceutical product found to be 11 counterfeit, the illness sought to be cured is aggravated or physical 12 injury or suffering results therefrom, or be the proximate cause of 13 death or permanent disability of the victim or patient.

Any of the imposable penalties in Paragraphs (i), (ii) and (iii) above shall be accompanied by forfeiture, confiscation and destruction of the pharmaceutical product(s) found to be counterfeit and the equipment, instrument and other articles used in violation of this Act or this implementing rules and regulations.

- 18 A. Other Remedies
- 19a.filing of an appropriate proceedings against the registered20pharmacist with the Professional Regulations Commission for21imposition of the appropriate penalties as provided under22Republic Act No. 10918 or the Philippine Pharmacy Act or its23amendment;
- b. filing of criminal charges against the violator(s), which can be
 instituted independently from the administrative case: Provided,
 That the distnissal of the criminal case shall not lift the closure
 order, except when it is a dismissal on the merits or for lack of
 basis: *Provided*, further, That the withdrawal of the private

1 criminal complaint shall not be a ground for the dismissal of the 2 administrative proceedings; and 3 **Criminal Sanctions** Β. 4 The commission of any of the acts prohibited under Section 4 of this Act shall 5 be punished by: 6 a) imprisonment of not less than six (6) months and one (1) day but not 7 more than six (6) years for mere possession of counterfeit 8 pharmaceutical product as provided for in Section 4 (b) of this Act; or 9 b) imprisonment of six (6) years and one (1) day, but not more than ten 10 (10) years or a fine of not less than One hundred thousand pesos 11 (P100,000.00) but not more than Five hundred thousand pesos 12 (₽500,000.00) or both such imprisonment and fine at the discretion of 13 the court in any other case mentioned in Section 4 of the Act; or

1.1

- 14 c) imprisonment of not less than six (6) months and one (1) day, but not
 15 more than two (2) years and four (4) months if the counterfeit
 16 pharmaceutical product is intended for animals; or
- 17 d) imprisonment of not less than six (6) years and one (1) day but not 18 more than ten (10) years for any manufacturer, seller or distributor 19 who shall conceal, substitute, dispose or destroy any pharmaceutical 20 product as may have been segregated and sealed by the FDA, or who 21 shall break, alter or tamper any mark or seal used by the FDA to 22 identify those segregated drugs as provided for under Section 6(A) of 23 this Act. Any other person who breaks, alters or tampers any mark or 24 seal used by the FDA to identify the segregated pharmaceutical 25 product shall suffer the penalty of not less than six (6) months and one 26 (1) day, but not more than six (6) years imprisonment; or
- e) if, as a result of the use of the pharmaceutical product found to becounterfeit, the illness sought to be cured is aggravated or physical

injury or suffering results therefrom, a punishment of imprisonment
 from twelve (12) years to fifteen (15) years and a fine ranging from
 One hundred thousand pesos (#100,000.00) to Five hundred thousand
 pesos (#500,000.00) shall be meted out; or

f) should a counterfeit pharmaceutical product be the proximate cause of
death of a victim, who unknowingly purchased and took a counterfeit
pharmaceutical product, the penalty of life imprisonment and a fine of
Five hundred thousand pesos (₱500,000.00) to Five million pesos
(₱5,000,000.00) shall be imposed.

10 Provided that, any provision of law to the contrary notwithstanding, when any 11 of the acts declared unlawful and prohibited under Section 4 above is committed and 12 the amount of the counterfeit pharmaceutical product(s) involve (whether as a single 13 product or totality of different pharmaceutical products) is One Million Pesos 14 (P1,000,000.00) or more, as valued by the Food and Drug Administration, it shall be 15 deemed as an offense involving economic sabotage and punishable by life 16 imprisonment and a fine of Five Million Pesos (P5,000,000.00) to Ten Million Pesos 17 (₽10,000,000.00).

18 In case any Act prohibited in Section 4 of this Act is also punishable under 19 other laws, the offender shall, if warranted by the evidence, be prosecuted under 20 the law prescribing the highest benalty. When the sale, offering for sale, donation, 21 distribution, trafficking, or brokering of counterfeit pharmaceutical product, or the 22 sale of any punch, dye, plate or any other equipment or instrument designed to 23 print, imprint or reproduce the trademark, trade name or other identifying mark of 24 another registered producer or any likeness thereof, upon any pharmaceutical 25 product or device or its container or label without authority from the legitimate 26 owners of the trademark or trade name, as prohibited in Section 4 of this Act is 27 committed by, through and with the use of online service, the same shall also be 28 covered by the relevant provisions of Republic Act No. 10175 or the "Cybercrime" 29 Prevention Act of 2012". *Provided*, that the penalty to be imposed shall be one (1) 30 degree higher than that provided under this Act.

Sec. 10. *Inter-agency, Stakeholders and International Cooperation.* – All relevant inter-agency, other stakeholders and international instruments, programs, cooperation, and arrangements agreed, whether in regulatory or criminal matters, to the widest extent possible for the purposes of detection, investigation, suppression, proceedings or effective response concerning administrative or criminal offenses related to counterfeit pharmaceutical products, or for the collection of evidence, shall be given full force and effect

..

8 Sec. 11. *Establishments' Responsibilities.* – All pharmaceutical product 9 establishments, including the licensed and registered pharmacist under their employ, 10 shall ensure at all times that pharmaceutical products satisfy the requirements of 11 pharmaceutical products' laws and standards relevant to their activities in the 12 pharmaceutical product supply chain and that control systems are in place to 13 prevent or eliminate counterfeit pharmaceutical products.

Pharmaceutical product establishments shall be knowledgeable of the specific requirements and standards of pharmaceutical product laws and regulations relevant to their activities in the pharmaceutical product supply chain and the procedures adopted by the regulatory authority.

18 If a pharmaceutical product establishment considers or has reason to believe 19 that a pharmaceutical product which it produced, processed, imported, distributed, 20 sold, offered for sale is counterfeit, it shall immediately initiate procedures to 21 withdraw the pharmaceutical product in question form the market and inform the 22 regulatory authority.

Pharmaceutical product establishments shall allow inspection of their business
and collaborate with the regulatory authority on actions taken to avoid risks posed
by the counterfeit pharmaceutical product they have supplied.

Sec. 12. *Rapid Alert System.* – The rapid alert system in place for the notification of direct or indirect risk to human health due to counterfeit pharmaceutical product shall be strengthened by the FDA.

Sec. 13. Strengthening the Pharmacovigilance System. - Strengthening the
 Pharmacovigilance System.

..

Within one hundred twenty (120) days from effectivity of this Act, the FDA shall establish a pharmacovigilance unit within its CDRR with appropriate staffing of officers and personnel and experts and be regularly allocated with appropriate budget.

Sec. 14. *Training and Consumer Advocacy and Education.* – Training,
orientation, education, and other advocacy activities shall be regularly provided by
the FDA to pharmaceutical product establishments, communities, and other sectors
of the community.

A consumer advocacy and education program shall be developed and implemented by the FDA in partnership with relevant NGOs, private organizations, coalitions, academic institutions, or other relevant government agencies. The FDA shall allocate and provide funds for the development and implementation of training and consumer advocacy and education programs.

16 Sec. 15. *Appropriations.* - The amount necessary to carry out the provisions 17 of this Act shall be included in the General Appropriations Act for the year following 18 its enactment and every year thereafter

Sec. 16. *Enforcement and Implementation*. – The FDA of the Department of
Health is hereby authorized to administer and supervise the implementation of this
Act, subject to the applicable provisions of Republic Act No. 10175 or the
"Cybercrime Prevention Act of 2012".

Sec. 17. *Implementing Rules and Regulations*. – The FDA, in consultation with
the stakeholders, shall promulgate the implementing rules and regulations within
One Hundred Twenty (120) days from the effectivity of this Act.

Sec. 18. Interpretation and Construction in Favor of Protection of Public
 Health. – All doubts in the implementation and interpretation of the provisions of this

Act, including its implementing rules and regulations, shall be resolved in favor of
 protecting public health against counterfeit pharmaceutical products.

Sec. 19. *Separability Clause*. – If any provision of this Act is held invalid or unconstitutional, the same shall not affect the validity and effectivity of the other provisions hereof.

Sec. 20. *Repealing Clause.* – Republic Act No. 8203 is hereby repealed. All
other laws, decrees, executive orders and rules and regulations contrary to or
inconsistent with the provisions of this Act are hereby repealed, amended or
modified accordingly

Sec. 21. *Effectivity*. – This Act shall take effect fifteen (15) days after its
publication in the Official Gazette or in a newspaper of general circulation.

Approved,

4.1

۰.